Abstract
responses to therapies and helps identifying novel targets for immunotherapies [1] .
25
Clinical impact of the immune contexture in different primary tumors 26 
27
The immune contexture is a concept that emerged from studies mostly performed in confirming a previous report in ovarian cancer [3] . A closer histopathological analysis 32 of CRC tumors highlighted the fact that the T cells were not stochastically distributed 33 within the tumor microenvironment but were present in the center (CT) and the 34 invasive margin (IM) of the tumor nests [4] . The densities of memory CD8 + T cells in 35 both the CT and the IM were associated with favorable prognosis, as well as the 36 expression of genes encoding Th1 cytokines (IFN-γ, IL2) and cytotoxic mediators 37 (granzymes, granulysin) [4] . A comprehensive approach of all genes having any type of foster T cells activation [6] .
42
In parallel to these studies in CRC, our group has investigated the immune Lymphoid Structures (TLS), lymphoid aggregates that structurally resemble secondary 47 lymphoid organs [7] [8] . These formations are present in the invasive margin and in the switching, a marker of active germinal center (GC) [9] . These data led us to hypothesize 54 that TLS are sites where immune reactions toward tumor-associated antigens are 55 generated [10] Merkel cell carcinoma, Warthin tumor as well as melanoma (reviewed in [10] ). These 
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These classifications not only reveal pathological features of cancers but also offer 214 targets and predictive markers for immunotherapies (Table 1) .
215
The immune contexture and response to therapy 216 7 The immune microenvironment of tumors not only reflects the oncogenic processes of 217 a cancer in a patient, but is also a constitutive arm of cancer control and thus of 218 patient's clinical outcome. It is therefore likely that therapeutic interventions modifying 219 the immune contexture will result in profound changes in cancer evolution.
220
Characterizing the immune contexture or the corresponding molecular profile of a 221 tumor in a patient will allow clinicians to propose the most appropriate therapies. For 222 instance, MSI CRC tumors with high mutational load respond to PD1 axis blockade [35] . Germain, C., Gnjatic, S., Tamzalit, F., Knockaert, S., Remark, R., Goc, J., Lepelley, A., 
